Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI

The aim of this study was to investigate the safety and efficacy biodegradable-polymer sirolimus-eluting stents (BP-SES) compared with durable-polymer everolimus-eluting (DP-EES) in patients ST-segment elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is an effective treatment for STEMI, long-term outcomes are determined by profile newest generation drug-eluting stents. BIOSTEMI (A Comparison Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Everolimus-Eluting Patients Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention) investigator-initiated, multicenter, assessor-blind, randomized superiority trial using Bayesian methods. STEMI undergoing primary PCI within 24 h symptom onset were 1:1 ratio receive BP-SES (n = 649) or DP-EES 651). endpoint target lesion failure (TLF), composite cardiac death, vessel reinfarction, clinically indicated revascularization (TLR) at 2 years. Between April 2016 March 2018, 1,300 included. Baseline characteristics comparable between groups. Follow-up through years complete 1,221 (94%). At years, TLF occurred 33 (5.1%) treated 53 (8.1%) (rate ratio: 0.58; 95% credible interval: 0.40 0.84; posterior probability 0.998). difference driven lower incidence TLR (2.5% vs. 5.1%; rate 0.52; 0.30 0.87; 0.993). There no significant differences rates definite stent thrombosis arms. In PCI, superior respect ischemia-driven TLR. Intervention [BIOSTEMI]; NCT02579031)